Search Result

Results for "

platelet production

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Platelet-activating Factor Receptor (PAFR) (2) 5-HT Receptor (2) Apoptosis (2) COX (1) Endogenous Metabolite (1) HIF/HIF Prolyl-Hydroxylase (2) Integrin (3) Isotope-Labeled Compounds (2) Phosphodiesterase (PDE) (2) Phospholipase (1) PKC (2) Prostaglandin Receptor (2) Thrombopoietin Receptor (5) Toll-like Receptor (TLR) (2)
By Research Areas:	Cancer (5) Cardiovascular Disease (10) Endocrinology (1) Infection (1) Inflammation/Immunology (9)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Platelet-activating Factor Receptor (PAFR) PDGFR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0531

Triflusal

COX Inflammation/Immunology

Triflusal irreversibly inhibits the production of thromboxane-B2 in platelets by acetylating cycloxygenase-1.

Triflusal	COX	Inflammation/Immunology
Triflusal irreversibly inhibits the production of thromboxane-B2 in platelets by acetylating cycloxygenase-1.

HY-13463B

Avatrombopag hydrochloride 3 Publications Verification AKR-501 hydrochloride; E5501 hydrochloride; YM477 hydrochloride	Thrombopoietin Receptor	Cardiovascular Disease
Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-13463

Avatrombopag 3 Publications Verification AKR-501; E5501; YM477	Thrombopoietin Receptor	Inflammation/Immunology
Avatrombopag (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-13463A

Avatrombopag maleate AKR-501 maleate; E5501 maleate; YM477 maleate	Thrombopoietin Receptor	Inflammation/Immunology
Avatrombopag maleate (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag maleate mimics the biological activities of TPO. Avatrombopag maleate increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag maleate is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A .

HY-153239

Eltrombopag methyl ester	Thrombopoietin Receptor	Inflammation/Immunology
Eltrombopag methyl ester is a derivative of Eltrombopag, which is a thrombopoietin (Tpo) receptor agonist, which can promote platelet production and is used in research related to specific types of thrombocytopenia .

HY-13463BS

Avatrombopag-d8 hydrochloride AKR-501-d₈ hydrochloride; E5501-d₈ hydrochloride; YM477-d₈ hydrochloride	Isotope-Labeled Compounds Thrombopoietin Receptor	Cardiovascular Disease
Avatrombopag-d₈ (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A[1][2][3].

HY-132190

Hexanolamino PAF C-16 1-O-Hexa-decyl-2-acetyl-sn-glycero-3-phospho(N,N,N-trimethyl)-hexanolamine	Platelet-activating Factor Receptor (PAFR)	Cardiovascular Disease
Hexanolamino PAF C-16 (1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine) is a Platelet-activating Factor Receptor (PAFR) Modulator with partial agonist activity. Hexanolamino PAF C-16 induces platelet aggregation and macrophage production but fails to increase [Ca2+]i in platelets, suggesting that PAF receptors may interact with PAF receptors through Ca ²⁺-dependent and -independent pathways. Related to platelet aggregation .

HY-N2391

p-Hydroxycinnamic acid	Endogenous Metabolite Prostaglandin Receptor	Endocrinology
p-Hydroxycinnamic acid, a common dietary phenol, could inhibit platelet activity, with IC₅₀s of 371 μM, 126 μM for thromboxane B₂ production and lipopolysaccharide-induced prostaglandin E₂ generation, respectively.

HY-P1181

Pam2CSK4	Toll-like Receptor (TLR)	Inflammation/Immunology
Pam2CSK4, a lipopeptide, is a TLR6-independent TLR2 ligand and agonist. Pam2CSK4 promotes platelet aggregation, and increases platelet adhesion to collagen-coated surfaces in a TLR2/NF-κB/BTK-dependent manner. Pam2CSK4 also activates iNOS expression and NO production in mouse macrophages .

HY-P1181A

Pam2CSK4 TFA	Toll-like Receptor (TLR)	Inflammation/Immunology
Pam2CSK4 (TFA), a lipopeptide, is a TLR6-independent TLR2 ligand and agonist. Pam2CSK4 (TFA) promotes platelet aggregation, and increases platelet adhesion to collagen-coated surfaces in a TLR2/NF-κB/BTK-dependent manner. Pam2CSK4 (TFA) also activates iNOS expression and NO production in mouse macrophages .

HY-107613

R 59-022 1 Publications Verification DKGI-I; Diacylglycerol kinase inhibitor I	PKC 5-HT Receptor	Inflammation/Immunology
R 59-022 (DKGI-I) is a DGK inhibitor (IC₅₀: 2.8 µM). R 59-022 inhibits the phosphorylation of OAG to OAPA. R 59-022 is a 5-HT Receptor antagonist, and activates protein kinase C (PKC). R 59-022 potentiates thrombin-induced diacylglycerol production in platelets and inhibits phosphatidic acid production in neutrophils .

HY-107613A

R 59-022 hydrochloride 1 Publications Verification DKGI-I hydrochloride; Diacylglycerol kinase inhibitor I hydrochloride	PKC 5-HT Receptor	Infection Inflammation/Immunology Cancer
R 59-022 (DKGI-I) hydrochloride is a DGK inhibitor (IC₅₀: 2.8 µM). R 59-022 hydrochloride inhibits the phosphorylation of OAG to OAPA. R 59-022 hydrochloride is a 5-HT Receptor antagonist, and activates protein kinase C (PKC). R 59-022 hydrochloride potentiates thrombin-induced diacylglycerol production in platelets and inhibits phosphatidic acid production in neutrophils .

HY-106837

Israpafant Y 24180	Platelet-activating Factor Receptor (PAFR)	Inflammation/Immunology
Israpafant (Y-24180) is a potent, selective and long-acting platelet activation factor (PAF) receptor antagonist with IC₅₀s of 0.84 nM and 3.84 nM against PAF-induced human and rabbit platelet aggregation, respectively. Israpafant stimulates both extracellular Ca ²⁺ influx and intracellular Ca ²⁺ release in prostate cancer cells. Israpafant suppresses the allergic cutaneous reactions including eosinophilia, cytokine production, edema and erythema in mice .

HY-15468

IOX2 Maximum Cited Publications 9 Publications Verification	HIF/HIF Prolyl-Hydroxylase	Cancer
IOX2 is a specific prolyl hydroxylase-2 (PHD2) inhibitor with IC₅₀ of 22 nM. IOX2 regulates platelet function and arterial thrombosis by upregulating HIF-1α expression and inhibiting ROS production. IOX2 can be used in the study of thrombotic diseases .

HY-15468A

IOX2 sodium	HIF/HIF Prolyl-Hydroxylase	Cardiovascular Disease Cancer
IOX2 sodium is a specific prolyl hydroxylase-2 (PHD2) inhibitor with IC₅₀ of 22 nM. IOX2 sodium regulates platelet function and arterial thrombosis by upregulating HIF-1α expression and inhibiting ROS production. IOX2 sodium can be used in the study of thrombotic diseases .

HY-B0523

Anagrelide	Phosphodiesterase (PDE) Apoptosis	Cardiovascular Disease Cancer
Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36 nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-B0523S

Anagrelide-13C2,15N,d2	Apoptosis Phosphodiesterase (PDE) Isotope-Labeled Compounds	Cardiovascular Disease Cancer
Anagrelide- ¹³C₂, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Anagrelide (HY-B0523). Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36?nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action .

HY-17369

Tirofiban hydrochloride monohydrate 1 Publications Verification L700462 hydrochloride monohydrate; MK383 hydrochloride monohydrate	Integrin	Cardiovascular Disease
Tirofiban (L700462) hydrochloride monohydrate is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride monohydrate induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride monohydrate can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-17369B

Tirofiban 1 Publications Verification L700462; MK383	Integrin	Cardiovascular Disease
Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-17369A

Tirofiban hydrochloride L700462 hydrochloride; MK383 hydrochloride	Integrin	Cardiovascular Disease
Tirofiban (L700462) hydrochloride is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area .

HY-128039

17-Phenyl-ω-trinor-PGE2	Prostaglandin Receptor	Others
17-Phenyl-ω-trinor-PGE2 is a PGE2 (HY-101952) analog, which is an agonist for EP1 and EP3 receptor. 17-Phenyl-ω-trinor-PGE2 inhibits the PAF-induced aggregation of human platelet-rich plasma (PRP) and Cicaprost (HY-19583) induced Cyclic AMP (HY-B1511) production .

HY-108611

AACOCF3 2 Publications Verification Arachidonyl trifluoromethyl ketone	Phospholipase	Cardiovascular Disease
AACOCF3 (Arachidonyl trifluoromethyl ketone) is a cell-permeant trifluoromethyl ketone analog of arachidonic acid. AACOCF3 is a potent and selective slow binding inhibitor of the 85-kDa cytosolic phospholipase A2 (cPLA2). AACOCF3 blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. AACOCF3 inhibits glucose-induced insulin secretion from isolated rat islets. AACOCF3 has the potential for the research of cardiovascular disease .

Pam2CSK4	Toll-like Receptor (TLR)	Inflammation/Immunology
Pam2CSK4, a lipopeptide, is a TLR6-independent TLR2 ligand and agonist. Pam2CSK4 promotes platelet aggregation, and increases platelet adhesion to collagen-coated surfaces in a TLR2/NF-κB/BTK-dependent manner. Pam2CSK4 also activates iNOS expression and NO production in mouse macrophages .

Pam2CSK4 TFA	Toll-like Receptor (TLR)	Inflammation/Immunology
Pam2CSK4 (TFA), a lipopeptide, is a TLR6-independent TLR2 ligand and agonist. Pam2CSK4 (TFA) promotes platelet aggregation, and increases platelet adhesion to collagen-coated surfaces in a TLR2/NF-κB/BTK-dependent manner. Pam2CSK4 (TFA) also activates iNOS expression and NO production in mouse macrophages .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2391

p-Hydroxycinnamic acid	Monophenols Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Endogenous metabolite Disease Research Fields Endocrinology	Endogenous Metabolite Prostaglandin Receptor
p-Hydroxycinnamic acid, a common dietary phenol, could inhibit platelet activity, with IC₅₀s of 371 μM, 126 μM for thromboxane B₂ production and lipopolysaccharide-induced prostaglandin E₂ generation, respectively.

Cat. No.	Product Name	Chemical Structure

HY-13463BS

Avatrombopag-d8 hydrochloride
Avatrombopag-d₈ (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A[1][2][3].

Avatrombopag-d8 hydrochloride

Avatrombopag-d₈ (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A[1][2][3].

HY-B0523S

Anagrelide-13C2,15N,d2
Anagrelide- ¹³C₂, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Anagrelide (HY-B0523). Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36?nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action .

Anagrelide-13C2,15N,d2

Anagrelide- ¹³C₂, ¹⁵N,d₂ is ¹⁵N and deuterated labeled Anagrelide (HY-B0523). Anagrelide is a potent inhibitor of phosphodiesterase type III (PDE3) (IC₅₀=36?nM). Anagrelide, an imidazoquinazoline derivative, acts as an inhibitor of platelet aggregation. Anagrelide inhibits bone marrow megakaryocytopoiesis. Anagrelide decreases gastrointestinal stromal tumor (GIST) cell proliferation and promotes their apoptosis in vitro. Anagrelide is a platelet-lowering agent and plays in the antithrombopoietic action .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks